Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone212-297-0020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.82 million
Profitability
Miscellaneous
Employees313
OptionableOptionable
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million. View Synergy Pharmaceuticals' Earnings History.
When is Synergy Pharmaceuticals' next earnings date?
What price target have analysts set for SGYP?
5 equities research analysts have issued 12-month target prices for Synergy Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 2,768.4% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.
What is the consensus analysts' recommendation for Synergy Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.
Has Synergy Pharmaceuticals been receiving favorable news coverage?
News stories about SGYP stock have been trending very positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a drop in short interest in December. As of December 31st, there was short interest totalling 16,520,891 shares, a drop of 63.6% from the December 14th total of 45,331,866 shares. Based on an average daily trading volume, of 19,706,792 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the shares of the stock are sold short. View Synergy Pharmaceuticals' Current Options Chain.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include Minerva Neurosciences (NERV), Kadmon (KDMN), TapImmune (MRKR), Catalyst Pharmaceuticals (CPRX), Verrica Pharmaceuticals (VRCA), Urovant Sciences (UROV), Aclaris Therapeutics (ACRS), Savara (SVRA), Verastem (VSTM), Tyme Technologies (TYME), Intec Pharma (NTEC), Adamas Pharmaceuticals (ADMS), Axsome Therapeutics (AXSM), AVEO Pharmaceuticals (AVEO) and Acer Therapeutics (ACER).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)
- Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)
- Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
- Ms. Pam Cebulski, Sr. VP of Marketing
- Ms. Marianne Jackson, Sr. VP of Sales & Market Access
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $0.2789.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $69.18 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
What is Synergy Pharmaceuticals' official website?
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
